Procedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository
|
|
|
- Annabella Sims
- 10 years ago
- Views:
Transcription
1 Procedure for Requesting Biological Samples and Data from the Accelerated Cure Project MS Repository March 2009 The Accelerated Cure Project Blood, Tissue and Data Bank solicits proposals requesting biological samples from investigators studying the causes or triggers of MS and related demyelinating diseases. To request specimens, please follow these procedures: 1. Submit a written proposal to the Accelerated Cure Project using the attached form. This proposal will contain information about your research plan as well as the number and type of specimens required. The proposal must include a description of your plans for contributing the data generated from use of the specimens back to Accelerated Cure Project for incorporation into the sample database. These plans must include type of data to be contributed, expected timing of the contribution, and quality control mechanisms to be applied to the data before contribution. Proposals are accepted and reviewed year round. 2. Your proposal will be initially reviewed by Accelerated Cure Project staff for completeness, alignment with the purpose of the repository, and our ability to fulfill the request. You will be notified if any problems are found and given the opportunity to make appropriate changes. 3. After the preliminary review is complete, your proposal will be reviewed by the Accelerated Cure Project Repository Oversight Committee, composed of representatives from Accelerated Cure Project, the Transverse Myelitis Association, the collection sites, and others. This committee will make a recommendation regarding whether to grant your request. Factors influencing this recommendation include: Potential benefit to people with MS and/or related demyelinating diseases Scientific merit of the application Experience of the investigator Adequacy of plans for contributing data generated through use of the specimens Statistical validity of the study Use of techniques designed to minimize the specimen volume required, if nonrenewable specimens are requested Scale of experiment (data on more samples is preferred to fewer, inclusion of multiple diseases is preferred to a single disease) 4. Accelerated Cure Project will make the final decision on providing the samples and associated data. If Accelerated Cure Project cannot meet your needs, we will attempt to identify an appropriate alternative resource. If your proposal is approved, you will be sent a letter of approval with a commitment from Accelerated Cure Project to provide the necessary specimens along with a materials transfer agreement. If your proposal is not accepted, you will be sent a letter stating the concerns that prevented your proposal from being approved, and invited to resolve any remaining scientific issues so that the proposal may be resubmitted.
2 Request for Samples from the Accelerated Cure Project MS Repository Use as much space as you need to answer the questions. Date: Name of investigator: Investigator's institution: Address: Phone number: address: Fax number: Description of research to be performed and its benefit to people with MS or other demyelinating diseases, written in language understandable by non-researchers. Explain how the information to be generated by your research will potentially improve the lives of people with MS, TM, NMO, ADEM, ON, or a clinically isolated syndrome. For example, if your research could help to treat, cure, or diagnose these diseases, describe in simple language how the results would facilitate these outcomes.
3 Description of samples requested: Type(s) of sample (DNA, serum, etc.) needed Number and type(s) of subjects (MS, CIS, TM, ADEM, ON, NMO, controls) including special requests such as RRMS not on disease-modifying therapy or Controls both parents Any requirements concerning blood relationships between subjects (such as only one case per family, or only controls who are not genetically related to cases) Quantity/volume of each type of sample needed Contact Accelerated Cure Project at or if you have questions about sample availability. Detailed description of research to be performed using the samples: Description of techniques to be used in performing the experiment Description of results that are expected to be generated through this research Analysis of the statistical power of your proposed experiment Quality assurance/quality control processes to be followed What important questions regarding the etiology, pathogenesis, biomarkers, or diagnosis of MS and/or related demyelinating diseases will your study help to answer?
4 Description of data elements from case report form (CRF) or previously returned research data needed to accompany samples: Note: Our case report form can be downloaded here: Description of data to be returned to the Repository database upon completion of your experiment: Specific data elements that will be provided for each sample analyzed Data QA/QC processes to be followed Note that a grace period will be allowed between completion of the experiment and submission of your data to the repository database to allow for publication and securing of IP rights. Has your proposed study been approved by an IRB? If not, please describe your plans for obtaining IRB approval: Have you obtained full financial support for your study, including support for sample/data acquisition costs? Our pricing policy can be found here:
5 If not, please explain: How did you hear about the Accelerated Cure Project repository? Please direct all proposals and questions about the review process, and submit completed proposals to: Hollie Schmidt )
I. INTRODUCTION DEFINITIONS AND GENERAL PRINCIPLE
Final: Approved by Partners Professional and Institutional Conduct Committee 8/11/04 Policy on Transfers to Third Parties Of Tissues, Other Specimens, and Data Obtained by Partners-Affiliated Providers
J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S
J D R F R E Q U E S T S E X P R E S S I O N S O F I N T E R E S T F O R : C O M B I N AT I O N T H E R AP I E S I N T Y P E 1 D I A B E T E S PURPOSE JDRF, the world s leading non-profit organization with
IRB REVIEW OF USE OF RESEARCH REPOSITORIES
IRB Review of Research Data Repositories at the Portland VA Medical Center IRB REVIEW OF USE OF RESEARCH REPOSITORIES 1. PURPOSE: To set policies and procedures for appropriate establishment, review, approval,
J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H
J D R F R E Q U E S T S L E T T E R S O F I N T E N T F O R : B I O M AR K E R S O F P AN C R E A T I C B E T A C E L L S T R E S S AN D H E AL T H PURPOSE JDRF, the world s leading non-profit organization
Innovation Platform: Sudden Cardiac Death
Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration
Application for an Off-Site Tissue Banking Waiver at a Non-Profit or Academic Institution
Application for an Off-Site Tissue Banking Waiver at a Non-Profit or Academic Institution INSTRUCTIONS This form may be filled in and saved using Adobe Reader version 7.0 or higher. The full version of
IRB RESEARCH REPOSITORY COMPLIANCE PROGRAM. Susan Burner Bankowski, MS, JD Chair, OHSU IRB
IRB RESEARCH REPOSITORY COMPLIANCE PROGRAM Susan Burner Bankowski, MS, JD Chair, OHSU IRB Why a Policy Now? The regulations have always included oversight for research repositories, with guidance dating
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary
Research Involving Human Biological Materials: Ethical Issues and Policy Guidance Executive Summary Introduction Biomedical researchers have long studied human biological materials such as cells collected
AUBAGIO (teriflunomide) oral tablet
AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
STANDARD OPERATING POLICY AND PROCEDURE
STANDARD OPERATING POLICY AND PROCEDURE SUBJECT: Biospecimen Request and Release Policy Number: 500.0 Policy Date: 1/16/2009 Amendment Date: N/A Revision Date: 5-3-2010 I. INTRODUCTION AND PURPOSE The
2.1 Who first described NMO?
History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
Clinically isolated syndrome (CIS)
Clinically isolated syndrome (CIS) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would
How To Change Medicine
P4 Medicine: Personalized, Predictive, Preventive, Participatory A Change of View that Changes Everything Leroy E. Hood Institute for Systems Biology David J. Galas Battelle Memorial Institute Version
Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis
May 25, 2015 Contact: Shikha Virdi 905-919-0200 ext. 5504 Ontario Reimburses CIS Indication for REBIF, a First-Line Treatment for Multiple Sclerosis Rebif now reimbursed under Ontario Drug Benefit Program
Multiple Myeloma Research Foundation. 2015 Senior Research Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Senior Research Award Program Guidelines MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 SENIOR RESEARCH AWARD Program Description: The Multiple Myeloma Research Foundation
7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology)
7- Doctoral Degree in Public Health and Public Health Sciences (Majoring Microbiology) Students should fulfill a total of 44 credit hours: 1- Compulsory courses: 14 credit hours. 1504801, 1504802, 1504803,
Clinical Trials: Questions and Answers
Clinical Trials: Questions and Answers Key Points Clinical trials are research studies that test how well new medical approaches work in people (see Question 1). Every clinical trial has a protocol, which
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
Pl"OtocolDirector: Iris Schrijver _ IRB Approval Date: _June 20 2006 IRE Expiration Date: June 19, 2007 _ STANFORD SAMPLE CONSENT FORM
Protocol Title: Molecular genetic basis of sensorineural hearing Pl"OtocolDirector: Iris Schrijver IRB Approval Date: June 20 2006 IRE Expiration Date: June 19, 2007 STANFORD SAMPLE CONSENT FORM Please
10/31/2014. Much is unknown. What is npod? THE JDRF Network for the Pancreatic Organ Donor with Diabetes (npod):
THE JDRF Network for the Pancreatic Organ Donor with Diabetes (npod): a biobank and a collaborative project about the pathogenesis of type 1 diabetes Alberto Pugliese, MD 23 rd ADA Annual Conference on
BIOBANK QUALITY. [email protected] Office: 602-546-1285
BIOBANK QUALITY David F Carpentieri, M.D. Pediatric Pathologist and Biorepository Director, Phoenix Children s Hospital Assistant Professor of Pediatrics and Clinical Pathology, University of Arizona Assistant
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT
Human Research Protection Program University of California, San Diego ISSUES ON DNA AND INFORMED CONSENT Regulatory changes will occur for investigators studying human DNA The recent acceleration and widening
Centre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies
Centre for Biomarker Research in Medicine COMET Competence Centre for Excellent Technologies Why Biomarker Research? early diagnosis, often before manifestation identification of at-risk patients for new
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff
Guidance for Sponsors, Institutional Review Boards, Clinical Investigators and FDA Staff Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not
Wilson Disease Research and Care. Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD
Wilson Disease Research and Care Looking Forward Ann Arbor, Michigan September 6, 2014 Fred Askari MD, PhD The Future is Bright Improved Access to Care Improved Diagnostics Earlier Diagnosis New Treatments
THE LEE SCHIPPER MEMORIAL SCHOLARSHIP FOR SUSTAINABLE TRANSPORT AND ENERGY EFFICIENCY Contact: [email protected]
THE LEE SCHIPPER MEMORIAL SCHOLARSHIP FOR SUSTAINABLE TRANSPORT AND ENERGY EFFICIENCY Contact: [email protected] ACTION: Program guidance. DATES: Expressions of Interest (EoI): Expressions of
Roche Position on Human Stem Cells
Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with
Memorandum. Factual Background
Memorandum TO: FROM: SUBJECT: Chris Ianelli and Jill Mullan, ispecimen, Inc. Kristen Rosati and Ana Christian, Polsinelli, PC ispecimen Regulatory Compliance DATE: January 26, 2014 You have asked us to
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS
RESEARCH INVOLVING DATA AND/OR BIOLOGICAL SPECIMENS 1. Overview IRB approval and participant informed consent are required to collect biological specimens for research purposes. Similarly, IRB approval
USMLE Step 1. Content Description and General Information
USMLE Step 1 Content Description and General Information A Joint Program of the Federation of State Medical Boards of the United States, Inc., and the National Board of Medical Examiners This booklet updated
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant
2 Year (2013 15) CLL/SLL Research Initiative CLL/SLL Collaborative Grant Guidelines & General Instructions for Application KEY DATES: Application Release Date: December 12, 2012 Application Deadline: February
INVESTIGATOR-INITIATED RESEARCH GRANTS
Because breast cancer is everywhere, SO ARE WE. At Susan G. Komen for the Cure, we are committed to ENDING breast cancer forever by ENERGIZING SCIENCE to find the cures and ensuring QUALITY CARE for all
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
Department of Environmental Science, Policy, and Geography Bylaws. Article I. The Department of Environmental Science, Policy and Geography
Department of Environmental Science, Policy, and Geography Bylaws Passed: 1 December 2006 Revised: February, 2007; February, 2008; April, 2008; August, 2008; October 8th, 2009; The Department of Environmental
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
OHTAC Recommendation
OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the
Clinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
Multiple Myeloma Research Foundation. 2015 Research Fellow Award. Program Guidelines
Multiple Myeloma Research Foundation 2015 Research Fellow Award Program Guidelines Program Description: MULTIPLE MYELOMA RESEARCH FOUNDATION 2015 RESEARCH FELLOW AWARD The Multiple Myeloma Research Foundation
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA
MULTIPLE SCLEROSIS AUSTRALIA MULTIPLE SCLEROSIS RESEARCH AUSTRALIA Submission to the ACT Legislative Assembly Health, Ageing, Community and Social Services Inquiry into the exposure draft of the Drugs
Focus Biobank Inflammatory Bowel Disease
Focus Biobank Inflammatory Bowel Disease University Hospitals Leuven KU Leuven Isabelle Cleynen, PhD Inflammatory Bowel Disease Crohn s disease (CD) Entire GI tract Transmural Fistulas and/or strictures
Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)
Course Descriptions I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students) This course is offered during the first semester of the second year of the MD Program. It
50-State Survey of Laws Regulating the Collection, Storage, and Use of Human Tissue Specimens and Associated Data for Research
NATIONAL CANCER INSTITUTE CANCER DIAGNOSIS PROGRAM 50-State Survey of Laws Regulating the Collection, Storage, and Use of Human Tissue Specimens and Associated Data for Research R. Hakimian, J.D., M.P.H.
Guide to Completing a Graduate Degree
Guide to Completing a Graduate Degree Version 1 Fall 2013 Prepared by the Office of Research and Graduate Studies Version 1, Fall 2013 1 Table of Contents Completing a Graduate Degree at Pacific...2 Before
Press Release Description Thread
Mass Media 9-5-2013 Press Release Description Thread Scientific Advancement by three Cypriot Scientists Hope for a new innovative treatment for Multiple Sclerosis Dear Sir/Madam, Our company, PALUPA Medical
Regulatory Issues in Genetic Testing and Targeted Drug Development
Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types
Movember Clinical Trial Award (CTA)
Movember Clinical Trial Awards Part 1: Overview Participating Organisation (s) Funding Category Description The Movember Foundation and Prostate Cancer Foundation of Australia Movember Clinical Trial Award
University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol
University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of
STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005
STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 VerDate 14-DEC-2004 06:53 Jan 05, 2006 Jkt 039139 PO 00000 Frm 00001 Fmt 6579 Sfmt 6579 E:\PUBLAW\PUBL129.109 APPS10 PsN: PUBL129 119 STAT. 2550 PUBLIC LAW
Leukemia Drug Pathway Analyzer
Brochure More information from http://www.researchandmarkets.com/reports/2673689/ Leukemia Drug Pathway Analyzer Description: Extra value: One year of free online updates included with this product There
MEDICAL LABORATORY TECHNOLOGIST COMPETENCY PROFILE
Description of Work: Positions in this banded class perform a variety of bench procedures in a medical laboratory setting or perform a variety of procedures in multiple disciplines that aid in the diagnosis
Certified Employee Peer Assistance and Review (PAR) Program Washoe County School District
Certified Employee Peer Assistance and Review (PAR) Program Washoe County School District Overview of the PAR Program The purpose of the joint Washoe County School District (WCSD)/Washoe Education Association
Guidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
NC SBI QUALITY ASSURANCE PROGRAM
NC SBI QUALITY ASSURANCE PROGRAM for the SBI Reviewed by: Deputy Assistant Director Bill Weis Date: Approved by: Assistant Director Jerry Richardson Date: Originating Unit: SBI Effective Date: July 25,
E Lighting Group Holdings Limited 壹 照 明 集 團 控 股 有 限 公 司 (incorporated in the Cayman Islands with limited liability) Stock Code : 8222
1. ORGANIZATION E Lighting Group Holdings Limited 壹 照 明 集 團 控 股 有 限 公 司 (incorporated in the Cayman Islands with limited liability) Stock Code : 8222 TERMS OF REFERENCE OF AUDIT COMMITTEE The board (the
Clinical Trials of Disease Modifying Treatments
MS CENTER CLINICAL RESEARCH The UCSF MS Center is an internationally recognized leader in multiple sclerosis clinical research. We conduct clinical trials involving the use of experimental treatments,
Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070277/ Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of
POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.
POLICY AND PROCEDURES OFFICE OF NEW DRUGS Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics Table of Contents PURPOSE...1 BACKGROUND...2 POLICY...3 ROLES AND RESPONSIBILITIES...4
Disease Modifying Therapies for MS
Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks
TAKING PART IN CANCER TREATMENT RESEARCH STUDIES
For more infomation about Cancer Clinical Trials at Upstate Cancer Center please call Upstate Connect 1.800.464.8668 TAKING PART IN CANCER TREATMENT RESEARCH STUDIES Information provided by: National Cancer
Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070278/ Global Multiple Myeloma Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
Global Haemophilia Epidemiology and Patient Flow Analysis - 2015
Brochure More information from http://www.researchandmarkets.com/reports/3070298/ Global Haemophilia Epidemiology and Patient Flow Analysis - 2015 Description: The author announced the results of its Haemophilia
Mariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz
Therapeutic Plasma Exchange in Multiple Sclerosis Relapses Mariusz Stasiołek Neurology Department Polish Mother s Memorial Hospital Research Institute, Lodz MS heterogeneity Multiple Sclerosis differences
Review of diabetes care in London Health and Environment Committee
The London Assembly s Health and Environment Committee intends to review diabetes care in London. Aim of review The purpose of this review is for the Committee to understand the extent of diabetes prevalence
Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
targeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts
FDA Regulation of Whole Slide Imaging (WSI) Devices: Current Thoughts Clinical Laboratory Improvement Advisory Committee Meeting Centers for Disease Control and Prevention February 15, 2012 Tremel A. Faison,
Application for Research
Application for Research All research conducted within the Brooks Rehabilitation system or any entity or facility bearing the Brooks name, including the Brooks Rehabilitation Clinical Research Center,
Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center
Multiple Sclerosis Update Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center None Disclosures First of All. Why is my talk in the Neurodegenerative hour? I respectfully object! Case
INFORMATION FOR GRADUATE STUDENTS IN BIOCHEMISTRY. Department of Chemistry and Biochemistry Utah State University, Logan, Utah
Biochemistry Graduate Program Approved July 2014 INFORMATION FOR GRADUATE STUDENTS IN BIOCHEMISTRY Department of Chemistry and Biochemistry Utah State University, Logan, Utah The Department of Chemistry
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
RUCDR Infinite Biologics Cell Culture and Stem Cell Center
RUCDR Infinite Biologics Cell Culture and Stem Cell Center 10 MECHANICAL STORAGE (-70 C AND -80 C) CELL CULTURE LABORATORY 7 CELL LINE FREEZING/STORAGE 6 CELL LINE EXPANSION/ 4 SAMPLE ACCESSIONING MAINTENANCE
Clinical Trials and Screening: What You Need to Know
Scan for mobile link. Clinical Trials and Screening: What You Need to Know What is a Clinical Trial? At A Glance A clinical trial is a research study that tests how well new medical techniques work in
